16th World ADC San Diego Summit

Start: Monday, November 3, 2025 8:00AM
End: Thursday, November 6, 2025 4:00PM

As antibody-drug conjugates aspire to advance to earlier-line treatments, harnessing innovation has never been more important to redefine the oncology standard of care and provide long-term benefit to patients.

Returning as the annual touchpoint for the global community, the 16th World ADC San Diego is THE week to fully immerse yourself in all things antibody-drug conjugate, spotlighting the cutting-edge innovation empowering the industry to develop differentiated ADCs that show clear advantages against standard-of-care therapies with clinically meaningful patient benefit.

With 7 streams of end-to-end content spanning discovery chemistry, discovery biology, preclinical, translational medicine, clinical lessons, process and analytical development, and manufacturing and supply chain: this is your one-stop bioconjugate shop to bring your team up to speed with ADC fundamentals, get answers to the problems hindering your ADC R and D, and identify emerging trends to ensure you stay ahead of the curve.

Providing unparalleled networking opportunities with 1,400+ attendees from start-ups, biotechs, large pharma and leading service providers, anybody who is anybody in the ADC field will unite under one roof to innovate, collaborate, and redefine the standard of oncology care.

URLs:
Tickets: https://go.evvnt.com/3045679-2?pid=3698
Brochure: https://go.evvnt.com/3045679-3?pid=3698

Prices:
Drug Developer Pricing - Conference + Seminar Day + Workshop Day: USD 5297.00,
Drug Developer Pricing - Conference + Seminar Day OR Workshop Day: USD 4228.00,
Drug Developer Pricing - Conference Only: USD 3179.00,
Academic Pricing - Conference + Seminar Day + Workshop Day: USD 4655.00,
Academic Pricing - Conference + Seminar Day OR Workshop Day: USD 3657.00,
Academic Pricing - Conference Only: USD 2659.00,
Service Provider Pricing - Conference + Seminar Day + Workshop Day: USD 7575.00,
Service Provider Pricing - Conference + Seminar Day OR Workshop Day: USD 6177.00,
Service Provider Pricing - Conference Only: USD 4779.00

Speakers: Jagath Reddy Jununtula, Aarvik Therapeutics, David Belair, Abbvie, Michael Lucas, Abbvie, Regina Reilly, Abbvie, Ian Nessler, Abbvie, Hetal Sarvaiya, Abbvie, Nandini Rudra-Ganguly, Abbvie, James Purcell, Abbvie, Susan Yue, Abbvie, Weon-Kyoo You, ABL Bio, Francisco Velazquez, Abzena, Patrick van Berkel, ADC Therapeutics, Douglas Jocelyn, ADC Therapeutics, Tomohiro Fujii, Ajinomoto Bio-Pharma Services, Herbert Ogutum, Amgen Inc., Taishi Kusama, Astellas Pharma, Jay Harper, AstraZeneca, Lakshmi Amaravadi, AstraZeneca, Dawn Spiller, AstraZeneca, Puja Sapra, AstraZeneca, Benedicte Recolin, AstraZeneca, Mike Flanagan, Avidity Biosciences, Inc., Aaron Moss, Avidity Biosciences, Inc., Steve Walsh, Bicycle Therapeutics plc, Eric Rowinsky, BioCity Biopharma, Rakesh Dixit, Bionavigen, David Bramhill, Bramhill Biological Consulting, Vijaya Pattabiraman, Bright Peak Therapeutics, Xiaoxia Gong, Bristol Myers Squibb, Hui Wei, Bristol Myers Squibb, Giorgio Salciarini, BSP Pharmaceuticals, Wim Dokter, Byondis, Ashley Harp, CRB, Lena Jonsson, Cytiva, Dhiraj Gambhire, Daiichi Sankyo, Gerold Meinhardt, Daiichi Sankyo, Amit Khatri, Daiichi Sankyo, Caleb Lee, Daiichi Sankyo, Federico Nasroulah, Daiichi Sankyo, Sophia Xu, Daiichi Sankyo, Leo Marx, Debiopharm, Yang Qiu, Duality Biologics, Jessica Podoll, Eli Lilly and Co., John Flygare, Eli Lilly and Co., Adalynn Harris, Equity Bridge, Inna Vanshtein, Exelisis, Brian Mendelsohn, Exelisis, Engin Ayturk, Exelisis, Gail Lewis, Genentech, Chunze Li, Genentech, Marieke Verweij, Genmab, Antoine Venne, Gilead Sciences, Pralay Mukhopadhyay, GSK, Andras Strassz, Heidelberg Pharma, Andreas Pahl, Heidelberg Pharma, Bob Lutz, Iksuda Therapeutics, Jutta Deckert, Iksuda Therapeutics, Peter Senter, Independent, Rongliang Lou, Innovent Biologics, Dowdy Jackson, Jackson Consulting Group, Gary Borzillo, Johnson and Johnson, Laurie Tatalick, Laurie Tatalick Consulting, Sonia Jain, Mayo Clinic, Yun Yang, Merck and Co, Radhika Balasubramani, Merck and Co, Andrea Geist, Merck KGaA, Gilles Gallant, Mythic Therapeutics, Zhican Qu, Nanolattix, Christian Rohlff, Oxford BioTherapeutics, Candice Wong, Pfizer, I-Ming Wang, Pfizer, Sharsti Sandall, Pfizer, Cathy Guo, Pfizer, Bruna Scheuher, Pfizer, Jeffrey Settleman, Pfizer, Arati Rao, Pfizer, John Lambert, Queen's University Belfast, Xuefei Zhong, Regeneron, Travis Biechele, Shasqi Inc., Martin Steegmaier, SOTIO Biotech, Michaela Fojtu, SOTIO Biotech, Peter Szijj, Stanford University, Gang Yin, Sutro Biopharma, Hans-Peter Gerber, Sutro Biopharma, Helena Kiefel, Sutro Biopharma, Daniel Calarese, Sutro Biopharma, Krishna Bajjuri, Sutro Biopharma, Marc Robillard, Tagworks Pharmaceuticals, Matthew Dagwell, UCL, Charlie Bishop, UCL, Aditya Bardia, UCLA, Toru Kondo, University of Hokkaido, Greg Thurber, University of Michigan, Marie Zhu, WuXi XDC, Geoff Winters, Zymeworks